A Phase 2 interventional study of oxygen and medical air in Pulmonary Fibrosis, sponsored by University of Siena. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-01-29.
Sponsored by University of Siena · Phase 2, Interventional, and Supportive care
Patients with pulmonary fibrosis often desaturate on exercise. There are no data showing whether ambulatory oxygen can be useful to improve exercise capacity in this condition. Ambulatory ambulatory oxygen is often denied to these patients based on studies conducted on patients with chronic obstructive pulmonary disease, a completely different condition for physiopathology, prognosis, and response to therapy. We therefore planned a controlled study to verify the usefulness of ambulatory oxygen in patients with pulmonary fibrosis
Criteria for inclusion: Patients with a diagnosis of pulmonary fibrosis of any kind, with oxygen saturation >90% in ambient air at rest, showing a desaturation \<88% during a preliminary 6 minutes walking test Criteria for exclusion: Inability to give consent, age \<18 or >85 years, walking problems from causes different from pulmonary disease
Procedure:
In a preliminary session, the flow of oxygen needed to prevent desaturation during walking is established according to a validated protocol Guyatt et al, Am J Respir Crit Care Med 2001,163:,942-946.) Two 6 minutes walking tests are then performed in a corridor, at least 30' apart, during administration of oxygen or medical air, in random order and double blind, at the same pre-determined flow, administered through a nasal cannula connected to a wall outlet (concealed from sight, being in a side rum at about mid distance in the corridor) through a 10 mt plastic tubing. Oxygen saturation and pulse rate are monitored through a dedicated recording oximeter (Minoxy, Cosmed) , whose display is concealed to both the patient and the operator, with an alarm set for oxygen saturation \<70%, to stop the test in case severe desaturation would occur Data are then transferred to computer for analysis only after both test are performed. Walked distance is recorded by the operator unaware of treatment.
At the end of each test, a short questionnaire is administered with 10 cm Visual Analogue Scales (VAS) for dyspnoea, fatigue, and preference compared to performing the test without any treatment. At the end of the second test a further scale is submitted, asking about the preference between the two treatments.
Primary outcomes are the distance walked and the difference in preference of the two treatments compared o no treatment. Secondary outcomes are differences in minimal saturation level and maximal pulse rate during the test and in the report of dyspnea and fatigue at the end of the test, and the reported preference between the two treatments.
Statistical analysis to evaluate the effect of the treatment on walking distance, heart frequency and oxygen saturation is performed using generalized linear model with a gaussian family and identity link and including order of treatment as a fixed effect. Parameters evaluated using VAS are analyzed using Koch adaptation of Wilkoxon rank test (Senn SS. Cross-over Trials in Clinical Research, 2nd Edition. Wiley 2002)
680 studies on the registry are indexed under Pulmonary Fibrosis; 119 are open to participants now.
This study's enrollment of 32 is below the median of 50 across 419 interventional studies indexed under Pulmonary Fibrosis.
Browse Pulmonary Fibrosis studies →University of Siena is the lead sponsor of 65 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
oxygen administered through a nasal cannula at a personalized, fixed flow
Drug: oxygen
Medical air administered through a nasal cannula at the same flow
Drug: medical air
information already included in arm/group descriptions.
Also known as: ambulatory oxygen
Placebo
Also known as: Placebo
distance walked
recorded by operator
Time frame: end of test (6 minutes)
Difference in preference of the two treatments compared to no treatment.
VAS scale
Time frame: end of test (6 minutes)
Difference in oxygen saturation level
Digitally recorded
Time frame: Walking test (6 min)
Difference in heart rate
Digitally recorded
Time frame: Walking test (6 min)
Difference in dyspnea at the end of test
VAS
Time frame: End of test (6 min)
Difference in fatigue at the end of test
VAS
Time frame: End of test (6 min)
Preference between the two treatments
VAS
Time frame: End of both tests (45 min)
No study locations are listed for this record.
Plan to share: No
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Siena